Cardionomic’s investors are positioned to achieve significant rewards.

The Cardionomic team has demonstrated high levels of capital efficiency in developing this breakthrough therapy and expects to demonstrate similar success moving forward.

 

 

Primary Patents

CAUTION: INVESTIGATIONAL DEVICE LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE.

©2016 Cardionomic, Inc. All Rights Reserved.

Privacy Notice/Terms of Use